NEPH · XBRL financial data

Nephros financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NEPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	8,561	10,404	9,975	14,238	14,162	18,789
Cost of goods and services sold	3,648	4,661	5,244	5,833	5,439	7,164
Gross profit	4,913	5,743	4,731	8,405	8,723	11,625
Research and development	2,759	2,166	1,255	873	906	1,339
Selling, general and administrative	6,466	7,710	7,593	8,911	7,676	9,000
Total operating expenses	9,188	10,078	9,066	9,998	8,717	10,479
Operating income (loss)	(4,275)	(4,335)	(4,335)	(1,593)	6	1,146
Interest expense	110	41	20	2	1	1
Other income (expense)	(152)	17	64	(44)	(10)	(78)
Income tax expense (benefit)	—	0	0	0	15	12
Net income (loss)	(4,526)	(3,867)	—	(1,575)	74	1,194
Earnings per share, basic USD per share	—	(0.41)	(0.73)	(0.15)	0.01	0.11
Earnings per share, diluted USD per share	—	—	(0.73)	(0.15)	0.01	0.11
Weighted average shares, basic thousands of shares	—	10,018	10,297	10,386	10,525	10,612
Weighted average shares, diluted thousands of shares	—	—	10,297	10,386	10,602	10,968

Fiscal years (NEPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	8,249	6,973	3,634	4,307	3,760	5,400
Accounts receivable	1,364	1,641	1,286	1,496	1,781	2,414
Inventory	5,304	4,795	3,153	2,470	2,615	3,232
Prepaid and other current assets	237	225	188	132	142	177
Total current assets	15,154	13,634	8,261	8,405	8,298	11,223
Property and equipment, net	295	366	116	152	161	106
Right-of-use asset	1,037	590	972	1,803	1,355	1,004
Goodwill	759	759	759	759	759	759
Total assets	18,510	17,650	10,999	11,861	11,210	13,641
Accounts payable	423	1,334	740	873	649	914
Accrued liabilities	341	444	285	794	565	1,462
Total current liabilities	1,325	2,390	1,412	2,113	1,562	2,767
Lease liability, non-current	759	340	700	1,390	1,046	661
Total liabilities	2,937	2,901	2,118	3,503	2,625	3,439
Accumulated deficit	(131,858)	(135,725)	(142,831)	(144,406)	(144,332)	(143,138)
Total stockholders' equity	12,522	11,695	5,592	8,358	—	—
Total liabilities and equity	18,510	17,650	10,999	11,861	11,210	13,641
Common shares outstanding (cover page) thousands of shares	9,912	10,258	10,461	10,544	10,600	10,644

Fiscal years (NEPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(4,526)	(3,867)	—	(1,575)	74	1,194
Stock-based compensation	779	1,259	982	1,052	153	296
Net cash from operating activities	(6,903)	(1,417)	(3,234)	827	(492)	1,645
Purchases of property and equipment	239	36	137	75	55	—
Net cash from investing activities	(239)	(85)	(137)	(75)	(50)	0
Proceeds from issuing common stock	11,452	—	—	—	—	—
Net cash from financing activities	11,216	237	34	(79)	(5)	(5)
Net change in cash	4,083	(1,276)	(3,339)	673	(547)	1,640

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Nephros	4,697	6,017	681*	10.9M	—	Q2 FY26 10-QJun 30, 2026
electroCore	8,501	9,450	(3,518)*	9.0M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
DarioHealth	6,634	not reported	(6,083)*	9.8M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
RenovoRx	9,479	909	(2,867)*	45.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026
United Health Products	24	0	(138)*	262.7M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Femasys	1,444	332	(3,936)*	8.4M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Cerenome	2,366	411	(7,132)*	7.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.